Antimycobacterial evaluation of pyrazinoic acid reversible derivatives

Current Pharmaceutical Design

Volumn 17, Issue 32, 2011, Pages 3506-3514

  Dolezal, Martin ^a   Kesetovic, Diana ^a   Zitko, Jan ^a  

^a Charles University in Prague Faculty of Pharmacy   (Czech Republic)

Author keywords

In vitro antimycobacterial evaluation; Pyrazines; Structure activity relationships

Indexed keywords

3 [[3 (TRIFLUOROMETHYL)PHENYL]AMINO]PYRAZINE 2,5 DICARBONITRILE; 5 (4 CHLOROBENZOYL)PYRAZINE 2 CARBOTHIOAMIDE; 5 [(3 METHOXYPHENYL)SULPHANYL]PYRAZINE 2 CARBOXYLIC ACID; 5 BUTYL 6 (PHENYLSULFANYL)PYRAZINE 2 CARBOTHIOAMIDE; 5 TERT BUTYL 6 CHLORO N (3 TRIFLUOROMETHYLPHENYL)PYRAZINE 2 CARBOXAMIDE; ANTIMYCOBACTERIAL AGENT; ETHYL 6 [(4 METHOXYPHENYL)SULPHANYL]PYRAZINE 2 CARBOXYLIC ACID; N (3 IODO 4 METHYLPHENYL)PYRAZINE 2 CARBOXAMIDE; N (3 TRIFLUOROMETHYLPHENYL)PYRAZINE 2 CARBOXAMIDE; PRODRUG; PYRAZINAMIDE; PYRAZINOIC ACID DERIVATIVE; UNCLASSIFIED DRUG;

ANTIBACTERIAL ACTIVITY; CONCENTRATION RESPONSE; CYTOTOXICITY; DRUG SCREENING; LIPOPHILICITY; MINIMUM INHIBITORY CONCENTRATION; MYCOBACTERIUM; NONHUMAN; PRIORITY JOURNAL; REVIEW; STRUCTURE ACTIVITY RELATION;

ANIMALS; ANTI-BACTERIAL AGENTS; CELL LINE; CELL SURVIVAL; DRUG DESIGN; HUMANS; MICROBIAL SENSITIVITY TESTS; MOLECULAR STRUCTURE; MYCOBACTERIUM; PRODRUGS; PYRAZINAMIDE; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 82055161621     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/138161211798194477     Document Type: Review

References (42)

1. WHO Report 2009 - Global Tuberculosis Control. Geneva: WHO Press, 2009, 1-7.
2. The Stop TB Partnership [homepage on the Internet]. World Health Organization [cited 2011 Jan10]. Available from: http://www.stoptb.org/assets/documents/global/plan/SSP_DRUGWG.pdf
3. Velayati AA, Masjedi MR, Farnia P, Tabarsi P, Ghanavi J, Ziazarifi AH, Hoffner SE. Emergence of new forms of totally drugresistant tuberculosis bacilli: super extensively drug-resistant tuberculosis or totally drug-resistant strains in Iran. Chest 2009: 136: 420-5.
4. Aldrich CC, Bosshoff HI, Remmel RP. Antitubercular Agents. In: Abraham DJ, Rotella DP. Burger's Medicinal Chemistry, Drug Discovery and Development. 7th ed. New York: Wiley 2010; vol. 7: 713-812.
5. Tuberculosis Antimicrobial Acquisition and Coordinating Facility (TAACF), Global discovery program for novel anti-tuberculosis drugs [homepage on the Internet]. The National Institute of Allergy and Infectious Diseases (NIAID) [cited 2011 Jan10]. Available from: http://www.taacf.org/
6. Zhang Y, Mitchison DA. The curious characteristics of pyrazinamide: a review. Int J Tuberc Lung Dis 2003; 7: 6-21.
7. Mitchison DA, Fourie PB. The near future: Improving the activity of rifamycins and pyrazinamide. Tuberculosis 2010; 90: 177-81.
8. Gratraud P, Surolia N, Besra GS, Surolia A, Kremer L. Antimycobacterial Activity and Mechanism of Action of NAS-91. Antimicrob Agents Chemother 2008; 52: 1162-6.
9. Zimhony O, Cox JS, Welch JT, Vilcheze C, Jacobs Jr. WR. Pyrazinamide inhibits the eukaryotic-like fatty acid synthase I (FAS I) of Mycobacterium tuberculosis. Nat Med 2000; 6: 1043-7.
10. Ngo SC, Zimhony O, Chung WJ, Sayahi H, Jacobs WR, Welch JT. Inhibition of isolated mycobacterium tuberculosis fatty acid synthase I by pyrazinamide analogs. Antimicrob Agents Chemother 2007; 51: 2430-5.
11. Sander P, Böttger EC. Mycobacteria: Genetics of resistance and implications for treatment. Chemother 1999; 45: 95-108.
12. Petrini B, Hoffner SE. Drug-resistant and multidrug-resistant tubercle bacilli. Int J Antimicrob Agents 1999; 13: 93-7.
13. Zhang Y, Post-Martens K, Denkin S. New drug candidates and therapeutic targets for tuberculosis therapy. Drugs Discov Today 2006; 11: 21-7.
14. Zhang Y. The magic bullets and tuberculosis drug targets. Annu Rev Pharmacol Toxicol 2005; 45: 529-64.
15. Mitchison DA. The search for new sterilizing anti-tuberculosis drugs. Front Biosci 2004; 9: 1059-72.
16. Bird CW. Heteroaromaticity, 5, a unified aromaticity index. Tetrahedron 1992; 48: 335-40.
17. Brown III CJ, Knaust JM. 2,5-Dimethylpyrazine 1,4-dioxide. Acta Cryst Sect E - Struct Rep Onl 2009; 65: o3052-sup-9.
18. Joule JA, Mills K. Heterocyclic chemistry. New York: Wiley 2010.
19. Maga JA. Pyrazine update. Food Rev Inter 1992; 8: 479-558.
20. Yamaguchi T. The relationship between the chemical structures of dihydropyrazine derivatives and DNA strand-breakage activity. Chem Pharm Bull 2007; 55: 532-6.
21. Dolezal M. Biologically Active Pyrazines of Natural and Synthetic Origin. Chem Listy 2006; 100: 959-66.
22. Kushner S, Dalalian H, Sanjurjo JL, et al. Experimental chemotherapy of tuberculosis. II. The synthesis of pyrazinamides and related compounds. J Am Chem Soc 1952; 74: 3617-21.
23. Cynamon MH, Klemens SP, Chou TS, Gimi RH, Welch JT. Antimycobacterial Activity of a Series of Pyrazinoic Acid Esters. J Med Chem 1992; 35: 1212-5.
24. Fernandes JPS, Pasqualoto KFM, Felli VMA, Ferreira EI, Brandt CA. QSAR Modeling od a set of pyrazinoate esters as antituberculotics prodrugs. Arch Pharm Chem Life Sci 2010; 343: 91-7.
25. Simões MF, Valente E, Gómez JRM, Anes E, Constantino L. Lipophilic pyrazinoic acid amide and ester prodrugs Stability, activation and activity against M. tuberculosis. Eur J Pharm Sci 2009; 37: 257-63.
26. Cynamon MH, Speirs RJ, Welch JT. In vitro antimycobacterial activity of 5-chloropyrazinamide. Antimicrob Agents Chemother 1998; 42: 462-3.
27. Dolezal M, Cmedlova P, Palek L, et al. Synthesis and Biological Evaluation of Pyrazinecarboxamides. Eur J Med Chem 2008; 42: 1105-13.
28. Dolezal M, Miletin M, Kunes J, Kralova K. Substituted amides of pyrazine-2-carboxylic acids, their synthesis and biological activity. Molecules 2002; 7: 363-73.
29. Dolezal M, Palek L, Vinsova J, Buchta V, Jampilek J, Kralova K. Substituted Pyrazinecarboxamides; Synthesis and Their Biological Evaluation. Molecules 2006; 11: 242-56.
30. Dolezal M, Kesetovicova D, Tumova L, Tuma J, Kralova K. Substituted N-phenylpyrazine-2-carboxamides, their synthesis and evaluation as the herbicides and the abiotic elicitors. Molecules 2007; 12: 2589-98.
31. Dolezal M, Zitko J, Kesetovicova D, Kunes J, Svobodova M. Substituted N-Phenylpyrazine-2-carboxamides: Synthesis and Antimycobacterial Evaluation. Molecules 2009; 14: 4180-9.
32. Dolezal M, Zitko J, Osicka Z, et al. Synthesis, antimycobacterial, antifungal and photosynthesis-inhibiting activity of chlorinated Nphenylpyrazine-2-carboxamides. Molecules 2010; 15: 8567-81.
33. Palek L, Dvorak J, Svobodova M, Buchta V, Jampilek J, Dolezal M. Synthesis, Antimycobacterial and Antifungal Evaluation of 3- arylaminopyrazine-2,5-dicarbonitriles. Arch Pharm 2008; 341: 61-5.
34. Krinkova J, Dolezal M, Hartl J, Pour M, Buchta V. Synthesis and biological activity of 5-alkyl-6-alkylsulfanyl-, resp. 5-arylsulfanylpyrazine-2-carboxamides and corresponding thioamides. Farmaco 2002; 57: 71-8.
35. Jampilek J, Dolezal M, Kunes J, Satinsky D, Raich I. Novel Regioselective Preparation of 5-Chloropyrazine-2-carbonitrile from Pyrazine-2-carboxamide and Coupling Study of Substituted Phenylsulfanylpyrazine-2-carboxylic Acid Derivatives. Curr Org Chem 2005; 9: 49-60.
36. Jampilek J, Dolezal M, Palek L, Buchta V. Antimicrobial Evaluation of Some Arylsulfanylpyrazinecarboxylic acid derivatives. Med Chem 2007; 3: 277-80.
37. Dolezal M, Jampilek J, Osicka Z, Kunes J, Buchta V, Vichova P. Substituted 5-aroylpyrazine-2-carboxylic acid derivatives: synthesis and biological activity. Farmaco 2003; 58: 1105-11.
38. Collins LA, Franzblau SG. Microplate Alamar blue assay versus BACTEC 460 system for high-throughput screening of compounds against Mycobacterium tuberculosis and Mycobacterium avium. Antimicrob Agents Chemother 1997; 41: 1004-9.
39. Pendalwar SL, Chaudhari DT, Patel MR. Antituberculous agents. II. Synthesis of some new N-substituted pyrazinamides. Bull Haffkine Inst 1980; 8: 102-6.
40. Stanovnik B, Tisler M, Golob V, Hvala I, Nikolic O. Heterocycles. CXCVIII. Heteroacyl azides as acylating agents for aromatic or heteroaromatic amines. J Het Chem 1980; 17: 733-6.
41. Kantardjieff K, Rupp B. Structural Bioinformatic Approaches to the Discovery of New Antimycobacterial Drugs. Curr Pharm Design 2004; 10: 3195-211.
42. McDermott W, Tompsett R. Activation of pyrazinamide and nicotinamide in acidic environment in vitro. Am Rev Tuberc 1954; 70: 748-54.